Knockdown of NCOA5 suppresses viability, migration and epithelial‑mesenchymal transition, and induces adhesion of breast cancer cells

Tan,Yanfang; Liu,Fuhui; Xu,Pei

doi:10.3892/ol.2021.12955

Knockdown of NCOA5 suppresses viability, migration and epithelial‑mesenchymal transition, and induces adhesion of breast cancer cells

Authors:
- Yanfang Tan
- Fuhui Liu
- Pei Xu
View Affiliations

Affiliations: Department of Clinical Laboratory, People's Hospital of Deyang City, Deyang, Sichuan 618000, P.R. China, Department of Blood Transfusion, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China, Department of Pathology, People's Hospital of Deyang City, Deyang, Sichuan 618000, P.R. China
Published online on: August 1, 2021 https://doi.org/10.3892/ol.2021.12955
Article Number: 694

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear receptor coactivator 5 (NCOA5) has been reported to be involved in the regulation of several malignancies; however, to the best of our knowledge, its role in breast cancer is still unknown. The present study aimed to reveal the biological function of NCOA5 in breast cancer cells. NCOA5 expression in breast cancer tissues and cell lines was examined using reverse transcription‑quantitative PCR and western blotting. Small interfering RNA (siRNA) against NCOA5 (siNCOA5) was transfected into MDA‑MB‑453 and MCF‑7 cells to knock down NCOA5. MTT, transwell migration and cell adhesion assays were performed to determine cell viability, migration and adhesion abilities of breast cancer cells, respectively. In addition, the expression levels of N‑cadherin, Vimentin and E‑cadherin were examined by western blotting. It was revealed that NCOA5 expression was significantly increased in breast cancer tissues and cell lines. Knockdown of NCOA5 suppressed breast cancer cell viability and migration, and induced cell adhesion. Compared with those in cells transfected with non‑targeting negative control siRNA, the protein expression levels of N‑cadherin and Vimentin were significantly decreased, whereas the protein expression levels of E‑cadherin were significantly increased in cells transfected with siNCOA5. The present study demonstrated that knockdown of NCOA5 suppressed cell viability and migration, induced cell adhesion, and inhibited epithelial‑mesenchymal transition of breast cancer cells, indicating that NCOA5 may serve a tumor‑promoting role in breast cancer.

View Figures

View References

1	Januškevičienė I and Petrikaitė V: Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sci. 239:1170092019. View Article : Google Scholar : PubMed/NCBI
2	Wörmann B: Breast cancer: Basics, screening, diagnostics and treatment. Med Monatsschr Pharm. 40:55–64. 2017.PubMed/NCBI
3	Zeng Y, Zhang J, Meng J, Numthuam S and Naruse K: Application of multi-modal imaging mediated by iron carbon nanoparticles based on reinforcement learning in the diagnosis of breast nodules. J Nanosci Nanotechnol. 21:1154–1160. 2021. View Article : Google Scholar : PubMed/NCBI
4	Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV and Mitsis M: Breast cancer in young women: An overview. Updates Surg. 69:313–317. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhang Z and Teng CT: Estrogen receptor alpha and estrogen receptor-related receptor alpha1 compete for binding and coactivator. Mol Cell Endocrinol. 172:223–233. 2001. View Article : Google Scholar : PubMed/NCBI
6	Sauvé F, McBroom LD, Gallant J, Moraitis AN, Labrie F and Giguère V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 21:343–353. 2001. View Article : Google Scholar : PubMed/NCBI
7	Jiang C, Ito M, Piening V, Bruck K, Roeder RG and Xiao H: TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem. 279:27781–27789. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu CY and Feng GS: NCOA5, a molecular link between type 2 diabetes and liver cancer. Hepatobiliary Surg Nutr. 3:106–108. 2014.PubMed/NCBI
9	Liu X, Liu F, Gao S, Reske J, Li A, Wu CL, Yang C, Chen F, Luo R and Xiao H: A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Lett. 391:152–161. 2017. View Article : Google Scholar : PubMed/NCBI
10	Dhar D, Seki E and Karin M: NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet. Cell Metab. 19:6–7. 2014. View Article : Google Scholar : PubMed/NCBI
11	Facciorusso A and Barone M: Glucose intolerance and hepatocellular carcinoma: Recent findings for old diseases. Hepatobiliary Surg Nutr. 3:91–92. 2014.PubMed/NCBI
12	He J, Zhang W, Li A, Chen F and Luo R: Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 500:177–183. 2018. View Article : Google Scholar : PubMed/NCBI
13	Sun K, Wang S, He J, Xie Y, He Y, Wang Z and Qin L: NCOA5 promotes proliferation, migration and invasion of colorectal cancer cells via activation of PI3K/AKT pathway. Oncotarget. 8:107932–107946. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zheng ZC, Wang QX, Zhang W, Zhang XH and Huang DP: A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma. OncoTargets Ther. 11:307–311. 2018. View Article : Google Scholar : PubMed/NCBI
15	Ye XH, Huang DP and Luo RC: NCOA5 is correlated with progression and prognosis in luminal breast cancer. Biochem Biophys Res Commun. 482:253–256. 2017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ranhotra HS: Estrogen-related receptor alpha and cancer: Axis of evil. J Recept Signal Transduct Res. 35:505–508. 2015. View Article : Google Scholar : PubMed/NCBI
18	Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R and Xiao H: NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 24:725–737. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liang Y, Zhang T, Shi M, Zhang S, Guo Y, Gao J and Yang X: Low expression of NCOA5 predicts poor prognosis in human cervical cancer and promotes proliferation, migration, and invasion of cervical cancer cell lines by regulating notch3 signaling pathway. J Cell Biochem. 120:6237–6249. 2019. View Article : Google Scholar : PubMed/NCBI
20	Chen GQ, Tian H, Yue WM, Li L, Li SH, Qi L, Gao C, Si LB and Lu M: NCOA5 low expression correlates with survival in esophageal squamous cell carcinoma. Med Oncol. 31:3762014. View Article : Google Scholar : PubMed/NCBI
21	Wu Y, Wu J, Dong QR and Guo NZ: Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma. Oncol Lett. 15:1888–1892. 2018.PubMed/NCBI
22	Yuan X, Zhang L, Cui Y, Yu Y, Gao X and Ao J: NCOA5 is a master regulator of amino acid-induced mTOR activation and β-casein synthesis in bovine mammary epithelial cells. Biochem Biophys Res Commun. 529:569–574. 2020. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Zhang T, Qin S, Wang R, Li Y, Zhou Z, Chen Y, Wu Q and Su F: Effects of UPF1 expression on EMT process by targeting E cadherin, N cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line. Mol Med Rep. 19:2137–2143. 2019.PubMed/NCBI
24	Yamashita N, Tokunaga E, Iimori M, Inoue Y, Tanaka K, Kitao H, Saeki H, Oki E and Maehara Y: Epithelial Paradox: Clinical significance of coexpression of e-cadherin and vimentin with regard to invasion and metastasis of breast cancer. Clin Breast Cancer. 18:e1003–e1009. 2018. View Article : Google Scholar : PubMed/NCBI
25	Paolillo M and Schinelli S: Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 20:202019. View Article : Google Scholar
26	Diepenbruck M and Christofori G: Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
27	Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
28	Bill R and Christofori G: The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 589:1577–1587. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wong SHM, Fang CM, Chuah LH, Leong CO and Ngai SC: E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 121:11–22. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Liu G, Kang Y, Dong Z, Qian Q and Ma X: N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
31	Guo L, Zhang K and Bing Z: Application of a co expression network for the analysis of aggressive and non aggressive breast cancer cell lines to predict the clinical outcome of patients. Mol Med Rep. 16:7967–7978. 2017. View Article : Google Scholar : PubMed/NCBI